| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | CELZ-201 (AlloStem) Type 2 Diabetes — pilot (late-stage insulin‑dependent) — preclinical/early clinical follow-up | Pre-clinical | — | Subscribe to access the data. | Cell Therapies | Endocrine System | |
Pre-clinical data readout example | CELZ-201 (AlloStem) Type 2 Diabetes — pilot (late-stage insulin‑dependent) — preclinical/early clinical follow-up | Pre-clinical | — | Subscribe to access the data. | Cell Therapies | Endocrine System | |
Pre-clinical data readout example | CELZ-201 (AlloStem) Type 2 Diabetes — pilot (late-stage insulin‑dependent) — preclinical/early clinical follow-up | Pre-clinical | — | Subscribe to access the data. | Cell Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Creative Medical Technology Holdings, Inc.$0.91
-0.06 (-6.4%)
C 43Pipeline Score Fair Value Biotech · Clinical
Market Cap
8.84 M
EPS
-1.85
P/E Ratio
-
Value Trade
158.71 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
-
R&D Expenses
541.66 K
Operating CF
-1.32 M
Total Assets
6.44 M
Total Liabilities
307.65 K
Equity
6.11 M
D/E Ratio
12,345
8.64 %
Week
3.02 %
1 Month
25.79 %
3 Month
-14.03 %
6 Month
-98.45 %
5 Year
-99.97 %
All Time
Cash Data
Cash Position
5.72 M
Monthly Burn
441.00 K
Runway
11.1 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
351.21 K
52 Week Range
1.50 - 6.25
% held by Insiders
0.95 %
% held by Institutions
2.21 %
Enterprise Value
3.01 M
Total Shares
3.69 M
Short %
16.45 %
Float Shares
3.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Creative Medical Technology Holdings, Inc.
171Total events
10Upcoming
31Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 10
Event history 161
Q3 2026
◆Enrollment CompleteCELZ-201Trial
Expansion cohort enrollment completion expected
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 30, 2026
▼Equity OfferingCorporate
Agreements for exercise of warrants for $4.5 million gross proceeds
Jun 22, 2026
▲IND ClearanceCELZ-201IND
FDA clearance of ADAPT trial expansion cohort
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 22, 2026
▲Enrollment UpdateCELZ-201Trial
Expansion cohort enrollment >85%
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 22, 2026
▲Interim AnalysisCELZ-201Trial
Positive interim 180-day data
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 22, 2026
▲DSMB ReviewCELZ-201Trial
Favorable DSMB review
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 16, 2026
▲Other Regulator MilestoneEx-US Regulatory
Regulatory approval to proceed with BioDefense Burn Pit Initiative
burn pit and toxic exposuresource ↗
Jun 16, 2026
▲Enrollment MilestoneTrial
Nationwide virtual participant onboarding and data collection phase initiated
burn pit and toxic exposuresource ↗
Jun 2026
▲IND ClearanceOlastrocelIND
FDA cleared expansion of ADAPT trial to enroll additional cohort
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 2026
▲Enrollment UpdateOlastrocelTrial
Expanded ADAPT cohort more than 85% enrolled
chronic lower back pain associated with degenerative disc diseasesource ↗
Jun 2026
▲Trial InitiationTrial
Project PHOENIX advanced into nationwide AI-enabled virtual data collection phase
toxic burn pit exposuresource ↗
Jun 2026
▲Enrollment MilestoneTrial
Project PHOENIX advanced into nationwide AI-enabled virtual data collection phase targeting 1,000 veterans
toxic burn pit exposuresource ↗
Drug Pipeline Intelligence
C43
Pipeline Score $20M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored2.3x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 911)
Percentile RankCreative Medical Technology Holdings, Inc. carries a moderate pipeline score (43/100), with $2.2B risk-adjusted pipeline value, led by CELZ-201 Administration in Type 1 Diabetes (Phase 1), across $73B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CELZ-201 Administration Monoclonal antibody | Type 1 Diabetes | Phase 1 | NCT05626712 | 26% | $2.0B | RECRUITING | 18 | STALLED | C (40) | Jan 31, 2028 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CELZ-201 (Olastrocel) Fast Track | chronic lower back pain | — | 2026-06-22 | statistically significant, clinically meaningful improvements in functional disability (ODI%) and pain Read More | Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain Read More | |
CELZ-201 (Olastrocel) Fast Track | chronic lower back pain | — | 2026-06-22 | statistically significant, clinically meaningful improvements in functional disability (ODI%) and pain Read More | Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain Read More | |
CELZ-201 (Olastrocel) Fast Track | chronic lower back pain | — | 2026-06-22 | statistically significant, clinically meaningful improvements in functional disability (ODI%) and pain Read More | Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CELZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CELZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CELZ▼ -12.4%on this news· ran to -25% by day 3
Creative Medical Technology Holdings Issues Mid-Year Update
Creative Medical Technology Holdings has provided a mid-year update highlighting its progress in clinical programs for chronic lower back pain and osteoarthritis. The company is advancing Olastrocel towards Phase 3 readiness and has reported positive interim data from the ADAPT trial. Additionally, Ultrasome™ has shown promising results, and the company is expanding its biodefense initiatives. Overall, Creative Medical is focused on disciplined capital allocation and strategic partnerships.
Read more →CELZ▼ -48.2%on this news· ran to -59% by day 3shared move
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. has announced agreements for the immediate exercise of warrants, expected to generate approximately $4.5 million in gross proceeds. The warrants allow for the purchase of up to 2,790,340 shares at a reduced price of $1.60 each. The proceeds will be used for working capital and corporate purposes, with a transaction closing date set for June 30, 2026.
Read more →CELZ▼ -13.5%on this news
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical Technology Holdings has received FDA clearance to expand its ADAPT trial for CELZ-201 (Olastrocel) in chronic lower back pain patients. The trial will enroll an additional 15 patients using less than 90 mg of morphine equivalents per day. The expansion follows positive interim results from the original cohort, which demonstrated significant improvements in pain and functional disability. The company is preparing for Phase 3 discussions with the FDA, aiming to address the urgent need for non-opioid treatment options.
Read more →CELZ▼ -6.3%on this news· ran to -19% by day 3shared move
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
Creative Medical Technology Holdings, Inc. has advanced Project PHOENIX into a nationwide phase focused on AI-driven virtual data collection for veterans exposed to burn pits and toxic hazards. This initiative aims to onboard at least 1,000 veterans, utilizing a mobile app for data collection and field-capable logistics. The project seeks to create a comprehensive dataset to identify biomarkers and therapeutic targets related to toxic exposure.
Read more →CELZCreative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Creative Medical Technology Holdings, Inc. reported positive results from its pilot study of Ultrasome™, a cell-free regenerative therapy for knee osteoarthritis. The study achieved a 93% response rate, indicating significant improvements in patient mobility and pain reduction. The therapy is derived from the GMP-manufactured CELZ-201 and aims to expand treatment options for osteoarthritis, a condition affecting over 30 million adults in the U.S.
Read more →CELZCreative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
Creative Medical Technology Holdings has achieved its second International Nonproprietary Name (INN) milestone with the WHO for its autologous T-cell immunotherapy, CELZ-101, now proposed as 'etaroleucel'. This follows the earlier INN recognition of 'olastrocel' for CELZ-201, indicating strong regulatory progress in its expanding cell therapy pipeline aimed at high unmet medical needs.
Read more →CELZ▼ -11.2%on this news
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings announced positive interim results from its ADAPT trial for CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain. The trial showed significant improvements in functional disability and pain, confirming its efficacy and safety. The company is now focusing on regulatory engagement and commercialization planning.
Read more →CELZ▲ +9.3%on this news
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Creative Medical Technology Holdings has received regulatory approval for its BioDefense Inc. Burn Pit Initiative, enabling expanded research into the health effects of burn pit exposure among U.S. veterans. The initiative will utilize existing partnerships and infrastructure, eliminating the need for additional fundraising. This approval is seen as a pivotal moment for the company as it aims to develop AI-driven regenerative solutions to support veterans' health. The program is expected to enhance national biodefense capabilities.
Read more →CELZCreative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Creative Medical Technology Holdings, Inc. has completed patient enrollment in its FDA-cleared ADAPT trial for CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain. This milestone follows a positive safety review, indicating a favorable safety profile for the therapy. The company is now focused on data analysis and follow-up, aiming to generate impactful clinical results.
Read more →CELZCreative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
Creative Medical Technology Holdings has received approval from the World Health Organization for the name 'olastrocel' as the International Non-Proprietary Name for its lead allogeneic cell therapy, CELZ-201. This milestone is significant for regulatory positioning and global market clarity. The company aims to target major therapeutic areas with unmet medical needs, including chronic lower back pain and diabetes.
Read more →CELZ▼ -13%on this news· ran to -24% by day 3
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
Creative Medical Technology Holdings, Inc. has launched the BioDefense Inc. Veterans Initiative, aimed at addressing the long-term effects of burn pit exposure among U.S. veterans. This innovative program combines proprietary regenerative technologies with AI analytics to develop precision therapies. The initiative is supported by a partnership with Greenstone Biosciences, enhancing its capabilities in biodefense and veteran healthcare.
Read more →CELZ▼ -32.7%on this news· ran to -46% by day 3shared move
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. has announced agreements for the immediate exercise of warrants, which will generate approximately $4.2 million in gross proceeds. The company will issue new unregistered warrants as part of the transaction, which will be exercisable for five years following shareholder approval. The funds will be used for working capital and general corporate purposes.
Read more →CELZ▲ +5.4%on this news· ran to -33% by day 3shared move
Creative Medical Technology Holdings Issues Letter to Shareholders
Creative Medical Technology Holdings has issued a letter to shareholders highlighting significant advancements in 2025. The company is transitioning from proof-of-concept to clinical trials, focusing on regenerative stem cell therapies. With a robust intellectual property portfolio and integration of AI, Creative Medical aims to redefine regenerative medicine and enhance shareholder value.
Read more →CELZCreative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
Creative Medical Technology Holdings congratulated the 2025 Nobel Laureates for their work on regulatory T cells, which has influenced modern immunology. The company also announced the receipt of two U.S. patents for its ImmCelz™ platform, aimed at treating Type 1 diabetes and heart failure. CEO Timothy Warbington emphasized the potential of Tregs in regenerative immunotherapy.
Read more →CELZCreative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
Creative Medical Technology Holdings has received FDA Fast Track designation for CELZ-201-DDT, aimed at treating degenerative disc disease, a leading cause of chronic lower back pain. This designation allows for expedited FDA interactions and potential priority review, enhancing the therapy's path to market. The company highlights the therapy's promising safety and efficacy data, aiming to provide a non-addictive solution for patients.
Read more →CELZCreative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
Creative Medical Technology Holdings has received a Notice of Allowance from the USPTO for a patent related to the treatment of Type 1 Diabetes using modulated immune cells. The patent, which will be effective until at least 2040, supports the company's ImmCelz platform that utilizes reprogrammed immune cells. This development underscores the company's focus on regenerative immunotherapy and its ongoing clinical trials.
Read more →CELZCreative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
Creative Medical Technology Holdings has received a Notice of Allowance for a patent related to its ImmCelz product, aimed at treating heart failure and post-infarct pathological remodeling. This patent, effective until at least 2040, reinforces the company's position in regenerative medicine. The ImmCelz platform utilizes reprogrammed immune cells to enhance treatment efficacy for over five million heart failure patients in the U.S.
Read more →CELZ▼ -8.3%on this news· ran to -27% by day 3
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
Creative Medical Technology Holdings has received FDA clearance for an expanded dose escalation in its Phase 1/2 trial of CELZ-201-DDT, a cell therapy for chronic lower back pain. The trial has shown promising interim results, including significant pain reduction and improved mobility without serious adverse events. This regulatory milestone allows for optimized dosing, potentially accelerating the path to a pivotal Phase 3 trial.
Read more →CELZ▼ -29.3%on this news· ran to -41% by day 3
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has announced agreements for the immediate exercise of outstanding warrants, expected to generate around $3.7 million in gross proceeds. The warrants, originally issued in October 2024, allow holders to purchase shares at a current exercise price of $4.42 per share. In exchange for the immediate cash exercise, the company will issue new warrants for up to 1,674,208 shares at an exercise price of $3.75 each. The proceeds from this offering will primarily be used for working capital and general corporate purposes.
Read more →CELZCreative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential
Creative Medical Technology Holdings (CELZ) supports President Trump's executive order to expand IVF access, which aligns with its OvaStem® program. The initiative aims to lower IVF costs, currently between $12,000 and $25,000 per cycle, making treatment more accessible. OvaStem® has shown an 85% improvement in hormonal function and a 70% success rate in achieving healthy pregnancies. The company also seeks Orphan Drug Designation for Primary Ovarian Insufficiency, reinforcing its role in fertility innovation.
Read more →CELZCreative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine Procedure using AlloStem™
Creative Medical Technology Holdings announced positive mid-term follow-up data from its StemSpine pilot study utilizing AlloStem cells to treat chronic lower back pain. The study showcased a significant reduction in opioid dependency, with over 90% of patients not using opioids three years after the procedure. Additionally, the data revealed an 80% reduction in pain scores and a substantial improvement in patients' functional mobility. With no serious adverse events reported, these findings support the safety and efficacy of the StemSpine procedure.
Read more →CELZCreative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
Creative Medical Technology Holdings, Inc. reported positive one-year results from its AlloStem Type 2 Diabetes pilot study, with an 80% efficacy rate in reducing insulin dependency. The study involved 20 patients, and there were no serious adverse effects. The results validate the safety and efficacy of the CELZ-201 therapy, encouraging further development for late-stage Type 2 Diabetes and other potential applications. The company is committed to developing innovative solutions for diabetes treatment.
Read more →CELZCreative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
Creative Medical Technology Holdings has expanded its collaboration with Greenstone Biosciences to enhance the development of its human induced pluripotent stem cell (iPSC) platform for diabetes treatment using AI. This new agreement builds on the existing progress of Creative Medical's proprietary hypoimmune iPSC technology, which is currently in clinical trials. The partnership aims to improve insulin secretion and optimize the function of pancreatic islet cells, addressing major challenges in stem cell therapies. Additionally, the use of multi-gene editing technologies will help develop safer, more effective regenerative therapies that may eliminate the need for immunosuppression.
Read more →CELZ▲ +5.3%on this news· ran to +17% by day 3
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain
Creative Medical Technology Holdings announced promising initial data from the first cohort of its Phase 1/2 trial for CELZ-201-DDT, a stem cell-based treatment for chronic back pain from degenerative disc disease. The trial involved 10 participants, with no dose-limiting toxicities or serious adverse events reported. Encouraging preliminary efficacy signals indicate potential in alleviating back pain, leading to the independent Data Safety Monitoring Board's recommendation to proceed to the next cohort. The company plans to enroll more participants in early 2025 as they continue to assess the therapy's impact.
Read more →CELZCreative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has announced a successful interim safety review for its ADAPT clinical trial assessing CELZ-201. The independent Data Safety Monitoring Board concluded that the trial may proceed, affirming the safety of CELZ-201 as a treatment for chronic lower back pain. This positive milestone follows a rigorous 30-day toxicity assessment, encouraging further clinical development of this innovative therapy. The company remains committed to addressing the needs of patients with limited treatment options for their condition.
Read more →CELZ▼ -22.6%on this news
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PHOENIX
Creative Medical Technology Holdings announced a registered direct offering of 418,552 shares of its common stock priced at $4.42 per share, raising gross proceeds of approximately $1.85 million. The offering is being executed under Nasdaq rules and includes warrants for the purchase of additional shares. Proceeds will be used for working capital and corporate purposes. The offering is managed by Roth Capital Partners, with the closing expected around October 23, 2024, pending customary conditions.
Read more →CELZCreative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
Creative Medical Technology Holdings has launched an AI-driven program aimed at diagnosing and treating patients exposed to biological and chemical weapons. This program leverages the company's proprietary human induced pluripotent stem cells (iPSC) technology to provide personalized care based on individual genetic profiles. The CEO highlighted the program's readiness for implementation and noted the company's robust cash position, which alleviates the need for immediate fundraising. This initiative marks a significant step in integrating AI into biotechnology for enhanced treatment precision.
Read more →CELZCreative Medical Technology Holdings Provides Corporate Update
Creative Medical Technology Holdings (CELZ) provided an update on its recent achievements as it moves into the second half of 2024. The company highlighted several milestones, including FDA clearance for clinical trials and Orphan Drug Designation for its therapy addressing Type 1 Diabetes. Additionally, CELZ is focusing on the commercialization of its cell-based therapies and has reported positive financial positioning with adequate funds for upcoming operations. The firm encourages stockholders to approve a proposal to increase authorized shares, enhancing future flexibility for capital needs.
Read more →CELZCreative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
Creative Medical Technology Holdings, Inc. has announced the successful generation of induced pluripotent stem cell (iPSC)-derived islet cells capable of producing human insulin as part of its iPSCelz program. This development marks a significant milestone for the company and is expected to facilitate clinical applications of human islet cells and insulin production. CEO Timothy Warbington highlighted the importance of these achievements in saving research and development time and costs. The company is currently exploring strategic collaborations to advance these programs further.
Read more →CELZCreative Medical Technology Holdings Provides Corporate Update Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a...
Creative Medical Technology Holdings, Inc. provided a corporate update highlighting advancements in regenerative therapies for diabetes and chronic lower back pain. The company has received FDA clearance for a Phase I/II clinical trial of its StemSpine procedure and reported strong financial health with no long-term debt. Additionally, it continues to make progress with its AlloStem™ cell line and ImmCelz™ platform.
Read more →CELZCreative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a...
Creative Medical Technology Holdings has received IRB approval to advance its Phase 1/2 clinical trial for CELZ-201-DDT, a novel cell therapy aimed at treating chronic lower back pain. This trial will focus on the safety and efficacy of the AlloStem™ procedure, targeting patients with Degenerative Disc Disease. The company aims to provide a non-surgical alternative to current pain management methods, which often rely on opioids.
Read more →CELZCreative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a...
Creative Medical Technology Holdings has received FDA clearance to initiate a Phase 1/2 clinical trial for its StemSpine® therapy using AlloStem™ to treat chronic lower back pain. The trial will involve 30 participants and aims to assess the safety and efficacy of the treatment, which utilizes a proprietary allogenic cell line. The company emphasizes the potential of this therapy as a safer alternative to opioids for pain management.
Read more →CELZCreative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements Phoenix, AZ
Creative Medical Technology Holdings, Inc. has regained compliance with Nasdaq listing requirements after meeting the minimum bid price rule. The company's stock closed above $1.00 for ten consecutive trading days, correcting previous non-compliance issues. CEO Timothy Warbington expressed optimism regarding the company's future, backed by a strong financial position and ongoing development of regenerative therapeutics. The company believes it can meet its operating costs and capital expenditures through 2024.
Read more →CELZ▼ -25%on this news
Creative Medical Technology Holdings Announces Reverse Stock Split Phoenix, AZ
Creative Medical Technology Holdings has announced a reverse stock split at a ratio of 1 for 10, effective June 12, 2023. This move aims to increase the market price per share, ensuring compliance with the NASDAQ minimum bid price requirement. The total number of outstanding shares will decrease from approximately 14.1 million to 1.4 million, and the authorized shares will also be significantly reduced. Stockholders will see these changes automatically reflected in their accounts or can choose to exchange paper certificates.
Read more →CELZCreative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market Phoenix, AZ
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market Phoenix, AZ, December 3, 2021 - Creative Medical Technology Holdings, Inc. (the "Company") (NASDAQ:CELZ), a commercial stage biot
Read more →CELZCreative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market November 9, 2021 Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings, Inc. (the "Company"),
Read more →CELZCreative Medical Technology Holdings, Inc. to Launch Virtual Physician Focused on Telehealth Solutions for Regenerative Medicine
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings, Inc. to Launch Virtual Physician Focused on Telehealth Solutions for Regenerative Medicine March 23, 2021 Phoenix, AZ, - Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechn
Read more →CELZCreative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine Clinical Sites
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine Clinical Sites March 10, 2021 Phoenix, AZ, - Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative
Read more →CELZCreative Medical Technology Holdings Provides Update on ImmCelz FDA Application
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Provides Update on ImmCelz FDA Application March 3, 2021 - Phoenix, AZ (OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA's submission requiremen
Read more →CELZCreative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplant
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz Company Aims to Leverage Immune Modulatory Technology to Alleviate Need for Immune Suppressants after Transplantation February 16, 2021 Phoen
Read more →CELZCreative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board Clinical Stage Regenerative Medicine Company Plans to Develop Clinical Programs for Major Uses of ImmCelz Regenerative Immunotherapy Fe
Read more →CELZCreative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz Therapeutic Activity Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells ImmCelz Induces Surge of Therapeutic
Read more →CELZCreative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative Immunotherapy Company to Start Clinical Trial to Address 30 Billion Dollar
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative Immunotherapy Company to Start Clinical Trial to Address 30 Billion Dollar Stroke Market Using Novel Cel
Read more →CELZCreative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz Stroke Regenerative Activity Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem C
celz_ex991.htm EXHIBIT 99.1 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz Stroke Regenerative Activity Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem Cell Types December 22, 2020 -
Read more →CELZCreative Medical Technology Holdings Reports completion and submission of Clinical Trial Data on CaverStem Procedure for Drug Resistant Erectile Dysfunction Patients Patients Who Underwent Patented Penile Regenerative Pr
Creative Medical Technology Holdings Reports completion and submission of Clinical Trial Data on CaverStem Procedure for Drug Resistant Erectile Dysfunction Patients Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone Marrow Concentrate will be
Read more →CELZPatients Treated for Erectile Dysfunction Utilizing Company's Patented CaverStem Stem Cell Procedure with Significant Success Rate General corporate updates and plans for second half of 2019. Phoenix, AZ
Treated for Erectile Dysfunction Utilizing Company's Patented CaverStem Stem Cell Procedure with Significant updates and plans for second half of 2019. Phoenix, AZ, June 20, 2019 - Creative Medical Technology Holdings, Inc. (OTCQB: CELZ), a leading commercial stage biotechnol
Read more →CELZCreative Medical Technology Holdings, Inc. April 2019 Shareholder Update 9:15 AM ET 4/30/19 | PR Newswire PHOENIX
Creative Medical Technology Holdings, Inc. April 2019 Shareholder Update April 30, 2019 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: are releasing updates on a regular basis, we will only cover new activit
Read more →CELZCreative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. March 28, 2019 Shareholder Update NewswireMarch 28, 2019 28, 2019 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: activities: As previously reported, we are continu
Read more →CELZSHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Phoenix, AZ 2-12-19, (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of it's activities: This update addresses the goals se
SHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Phoenix, AZ 2-12-19, (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of it's activities: This update addresses the goals set for Q1 2019 with regard to the ongoing commercializat
Read more →CELZCreative Medical Technology Holdings, Inc. December 2018 Shareholder Update PHOENIX
Creative Medical Technology Holdings, Inc. December 2018 Shareholder PHOENIX, Dec. 27, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: As we end 2018 we look forward to continuing to reach multiple Cave
Read more →CELZCreative Medical Technology Holdings, Inc. Announces New Design To Caverstem Website Including New Features For Physician/Patient Engagement PHOENIX
Creative Medical Technology Holdings, Inc. Announces New Design To Caverstem Website Including New Features For Physician/Patient Engagement 6, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that as a continuation of
Read more →CELZShareholder Update: Creative Medical Technology Holdings, Inc. PHOENIX
Update: Creative Medical Technology Holdings, Inc. 17, 2018 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities: Creative Medical Health, Inc. shall convert $100,000.00 of deferred management compensation to CELZ
Read more →CELZSHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Phoenix, AZ 8-14-18, (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities. Debt : Since our last 8k
SHAREHOLDER UPDATE: CREATIVE MEDICAL TECHNOLOGY Phoenix, AZ 8-14-18, (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities. Debt: Since our last 8k on debt reduction an additional $268,858.00 has been extinguished. Cave
Read more →CELZSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this " Agreement ") is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of August 8, 2018, between Creative Medical Technology Holdings, Inc., a Nevada corporation and its predecessors (the "Company"), and each purchaser identified on the signature page
Read more →CELZCompany Sees Possible Access to AmnioStemTM for Cancer Patients under "Right to Try" Law PHOENIX
Company Sees Possible Access to AmnioStemTM for Cancer Patients under "Right to Try" Law PHOENIX, July 6, 2018 /PRNewswire/ - Creative Medical Technology Holdings, Inc. (CELZ) announced today initiation of a program aimed at treating cancer associated wasting, through the in-
Read more →CELZCreative Medical Technology Holdings Forms CaverStem International LLC Subsidiary to concentrate on International Erectile Dysfunction Market PHOENIX and
Creative Medical Technology Holdings Forms CaverStem International Subsidiary to concentrate on International Erectile Dysfunction PHOENIX and LOS ANGELES, June 19, 2018 /PRNewswire/ - Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CaverStem
Read more →CELZStem Cell Clinical Trial Expert to join Scientific Advisory Board (
Stem Cell Clinical Trial Expert to join Scientific Advisory Board (June 4, 2018 Phoenix, AZ - Los Angeles, CA) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that Timothy Henry MD has joined the Scientific Advisory Dr. Henry, an expert kn
Read more →CELZCreative Medical Technology Holdings Files Patent on Anti-aging Technology Using AmnioStem Stem Cells Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of
Creative Medical Technology Holdings Files Patent on Anti-aging Technology Using AmnioStem Stem Cells Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of its AmnioStemTM stem cells as a means of reducing/reversi
Read more →CELZShareholder Update: Creative Medical Technology Holdings, Inc. Continues To Extinguish Debt PHOENIX
Shareholder Update: Creative Medical Technology Holdings, Inc. Continues To Extinguish Debt PHOENIX, April 30, 2018 /PRNewswire/ - Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that debt to two lenders in the amount of $163,000.00 has As previously a
Read more →CELZAMENDMENT TO 8% PROMISSORY NOTE This Amendment to the 8% Promissory Note (this " Amendment "), dated effective
TO 8% PROMISSORY NOTE This Amendment to the 8% Promissory Note (this "Amendment"), dated effective April 11, 2018, is by, between, and among Creative Medical Technologies, Inc., a Nevada corporation (the "Borrower"), Creative Medical Health, Inc., a Delaware corporation (the
Read more →CELZCreative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem Procedure For Erectile Dysfunction At International Urology Conference PHOENIX
Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem Procedure For Erectile Dysfunction At International Urology Conference PHOENIX, March 26, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) will be exhibiting it's patented C
Read more →CELZCreative Medical Technology Holdings, Inc. announces continued recruitment of Physicians for it's patented and clinically tested Stem Cell treatment for Erectile Dysfunction (
Creative Medical Technology Holdings, Inc. announces continued recruitment of Physicians for it's patented and clinically tested Stem Cell treatment for Erectile (January 31, 2018 - Phoenix, AZ) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced tod
Read more →CELZStem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract Optimism Creative Medical Technology Holdings, Inc (OTCQB:CELZ) provides the following discussion on a recent US News and World
Stem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract Optimism Creative Medical Technology Holdings, Inc (OTCQB:CELZ) provides the following discussion on a recent US News and World Report article1 addressing advances of adult stem cells
Read more →CELZUrologist to the Stars" Dr. Alexander Gershman Begins Treating Patients with Patented Caverstem TM Stem Cell Procedure for Drug Refractory Erectile Dysfunction (
"Urologist to the Stars" Dr. Alexander Gershman Begins Treating Patients with Patented CaverstemTM Stem Cell Procedure for Drug Refractory Erectile (December 18, 2017 - Phoenix, AZ/Los Angeles, CA) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced
Read more →CELZCreative Medical Technology Holdings Recruits Top Urologists for Caverstem TM Stem Cell Treatment of Erectile Dysfunction (
Creative Medical Technology Holdings Recruits Top Urologists for CaverstemTM Stem Cell Treatment of Erectile Dysfunction (December 13, 2017 - Phoenix, AZ) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today recruitment of leading urologists in
Read more →CELZMANAGEMENT REIMBURSEMENT AGREEMENT THIS MANAGEMENT REIMBURSEMENT AGREEMENT (this " Agreement "), executed this 17 th day of November 2017, is by and between Creative Medical Health, Inc., a Delaware corporation (" CMH ")
MANAGEMENT REIMBURSEMENT AGREEMENT THIS MANAGEMENT REIMBURSEMENT AGREEMENT (this "Agreement"), executed this 17th day of November 2017, is by and between Creative Medical Health, Inc., a Delaware corporation ("CMH"), Creative Medical Technology Holdings, Inc., a Nevada corpora
Read more →CELZAMENDMENT AND WAIVER TO THE PATENT PURCHASE AGREEMENT THIS AMENDMENT and WAIVER , dated as of
AMENDMENT and WAIVER, dated as of November 14, 2017, (this "Amendment") to the Patent Purchase Agreement referred to below is entered into by and between StemSpine, LLC, a Nevada limited liability company ("StemSpine"), a wholly owned subsidiary of Creative Medical Technologies
Read more →CELZCreative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction. Trial Results Support Initiation of Urologist Outreach and Commercialization
Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction. Trial Results Support Initiation of Urologist Outreach and Commercialization October 18, 2017 Phoenix, AZ, Creative Medical Technology Holdings (OTCQB - CELZ) anno
Read more →CELZCreative Medical Technology Holdings Expands Personalized Minimally Manipulated Stem Cell Therapeutic Platform by Entry into Field of Stroke and Neurodegeneration Regenerative Medicine Company Files Patent on Practice of
Creative Medical Technology Holdings Expands Personalized Minimally Manipulated Stem Cell Therapeutic Platform by Entry into Field of Stroke and Neurodegeneration Regenerative Medicine Company Files Patent on Practice of Medicine Procedure to Address Stroke Phoenix, AZ, Octo
Read more →CELZCreative Medical Technology Holdings Achieves 100% Patient Enrollment in Caverstem TM Clinical Trial for Stem Cell Treatment of Erectile Dysfunction Company on Schedule for 2018 Commercialization of its Patented Caverste
Creative Medical Technology Holdings Achieves 100% Patient Enrollment in CaverstemTM Clinical Trial for Stem Cell Treatment of Erectile Dysfunction Company on Schedule for 2018 Commercialization of its Patented CaverstemTM Procedure to Treat Erectile Dysfunction in Patients wh
Read more →CELZCreative Medical Technology Holdings Demonstrates AmnioStem Derived Exosomes Inhibit Glioma Growth Company's Unique Stem Cell Nanotechnology Approach Appears to Stimulate Regeneration of Healthy Brain Cells While Selecti
Creative Medical Technology Holdings Demonstrates AmnioStem Derived Exosomes Inhibit Glioma Growth Company's Unique Stem Cell Nanotechnology Approach Appears to Stimulate Regeneration of Healthy Brain Cells While Selectively Inhibiting Glioma Brain Cancer SAN DIEGO and PHOENI
Read more →CELZCreative Medical Technology Holdings Adds Immune Modulatory Cells for Stimulation of Perispinal Angiogenesis to Induce Regeneration of Degenerated Discs Company Expands Intellectual Property Portfolio in Lower Back Pain
Creative Medical Technology Holdings Adds Immune Modulatory Cells for Stimulation of Perispinal Angiogenesis to Induce Regeneration of Degenerated Discs Company Expands Intellectual Property Portfolio in Lower Back Pain Indication PHOENIX, AZ, SAN DIEGO, CA, June 21, 2017/PR
Read more →CELZCreative Medical Technology Holdings Develops Platform Aimed at Augmenting All Mesenchymal Stem Cell Therapies for Lower Back Pain Company files Patent to Increase Circulation around Stem Cell Implantation Sites to Impro
Creative Medical Technology Holdings Develops Platform Aimed at Augmenting All Mesenchymal Stem Cell Therapies for Lower Back Pain Company files Patent to Increase Circulation around Stem Cell Implantation Sites to Improve Effects of Cellular Therapies PHOENIX, June 7, 2017
Read more →CELZCreative Medical Technology Holdings, Inc. Files Patent on AmnioStem Mediated Immune Reprogramming for Stroke Company Discovers Novel Method of Suppressing Inflammation Using Combination Autologous Allogeneic System
Creative Medical Technology Holdings, Inc. Files Patent on AmnioStem Mediated Immune Reprogramming Company Discovers Novel Method of Suppressing Inflammation Using Combination Autologous Allogeneic May 24, 2017 - Phoenix, AZ and San Diego, CA, Creative Medical Technology H
Read more →CELZCreative Medical Technology Holdings to Expand into 10 Billion Dollar per Year Lower Back Pain Market with Acquisition of Issued US Stem Cell Patent Clinical Stage Stem Cell Company Continues Aggressive Pursuit of Person
Medical Technology Holdings to Expand into 10 Billion Dollar per Year Lower Back Pain Market with Acquisition of Issued US Stage Stem Cell Company Continues Aggressive Pursuit of Personalized, Rapid to Implement, Autologous Regenerative Medicine May 18, 2017 Creative Medical Te
Read more →CELZCreative Medical Technology Holdings Files Patent on Reducing Radiation Toxicity Using AmnioStem Universal Donor Stem Cell Product Company Aims to Leverage Stem Cell Neuroregenerative Activity to Reduce Adverse Effects o
Creative Medical Technology Holdings Files Patent on Reducing Radiation Toxicity Using AmnioStem Universal Donor Stem Cell Product Company Aims to Leverage Stem Cell Neuroregenerative Activity to Reduce Adverse Effects of Brain Radiation SAN DIEGO and PHOENIX, March April 4,
Read more →CELZCreative Medical Technology Holdings Appoints Internationally Renowned Stem Cell Pioneer as Chief Scientific Officer Clinical Stage Stem Cell Company to Accelerate Product Development Leveraging Experience of Dr. Thomas
Creative Medical Technology Holdings Appoints Internationally Renowned Stem Cell Pioneer as Chief Scientific Officer Clinical Stage Stem Cell Company to Accelerate Product Development Leveraging Experience of San Diego, CA, Phoenix, AZ, March 8, 2017 - Creative Medical Techn
Read more →CELZCreative Medical Technology Holdings Announces Initiation of In House Research Program at San Diego BioLabs Clinical Stage Stem Cell Company Expands Translational Research Activities with Acceptance into Premier San Dieg
Creative Medical Technology Holdings Announces Initiation of In House Research Program at San Diego BioLabs Clinical Stage Stem Cell Company Expands Translational Research Activities with Acceptance into Premier San Diego Research Facility PHOENIX, AZ, and SAN DIEGO, CA, Febr
Read more →CELZCreative Medical Technology Holdings Files Patent on AmnioStem Stroke Therapy Collaboration between Stem Cell Clinician, Neurologist, and Cell Therapy Developer Results in Novel Regenerative Approach to Stroke PHOENIX an
Medical Technology Holdings Files Patent on AmnioStem Stroke Therapy Collaboration between Stem Cell Clinician, Neurologist, and Cell Therapy Developer Results in Novel Regenerative Approach to Stroke PHOENIX and SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Creative Medical Techn
Read more →CELZCreative Medical Technology Holdings Recruits Internationally Renowned Neurologist to Assist in Clinical Development of AmnioStem Stem Cell Therapy for Stroke Clinical Stage Stem Cell Therapeutics Company Aims to Develop
Creative Medical Technology Holdings Recruits Internationally Renowned Neurologist to Assist in Clinical Development of AmnioStem Stem Cell Therapy for Stroke Clinical Stage Stem Cell Therapeutics Company Aims to Develop "Universal Donor" Stem Cell "Drug" for Stroke Patients
Read more →CELZCreative Medical Technology Holdings Announces Creation of Amniotic Fluid Stem Cell Focused Subsidiary AmnioStem LLC Clinical Stage Stem Cell Therapeutics Company Expands Regenerative Medicine Portfolio to 'Off-the-Shelf
Creative Medical Technology Holdings Announces Creation of Amniotic Fluid Stem Cell Focused Subsidiary AmnioStem LLC Clinical Stage Stem Cell Therapeutics Company Expands Regenerative Medicine Portfolio to 'Off-the-Shelf Allogeneic Stem Cell Products Phoenix, AZ, November 16
Read more →CELZCreative Medical Technologies Receives Exclusive License to Key Amniotic Fluid Stem Cell Patent from University of California System Patent Rights Cover Multipotent Amniotic Fetal Stem Cells Phoenix, AZ
Creative Medical Technologies Receives Exclusive License to Key Amniotic Fluid Stem Cell Patent from University of California System Patent Rights Cover Multipotent Amniotic Phoenix, AZ, November 2, 2016-Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today
Read more →CELZCreative Medical Technology Holdings, Inc. Recruits Internationally Renowned Urologic Surgery Pioneer Dr. Alexander Gershman to Scientific Advisory Board Clinical Stage Company Developing Stem Cell Therapy for Treatment-
Creative Medical Technology Holdings, Inc. Recruits Internationally Renowned Urologic Surgery Pioneer Dr. Alexander Gershman to Scientific Advisory Board Clinical Stage Company Developing Stem Cell Therapy for Treatment-Refractory Erectile Dysfunction Recruits "Doctor to the S
Read more →CELZCreative Medical Technology Holdings Expands Adult Stem Cell Therapeutic Platform to Combat Female Infertility Caused by Premature Ovarian Failure Company Files Patent on Rejuvenating Ovaries through Use of Endothelial P
Creative Medical Technology Holdings Expands Adult Stem Cell Therapeutic Platform to Combat Female Infertility Caused by Premature Ovarian Failure Company Files Patent on Rejuvenating Ovaries through Use of Endothelial Progenitor Cell Stem Cells PHOENIX, Arizona, August 24,
Read more →CELZCreative Medical Technologies Completes Proof-of-Concept Studies at Preventing Miscarriages Using Stem Cell Immunotherapy Clinical Stage Erectile Dysfunction Company Expands Product Pipeline into Reproductive Immunology
Creative Medical Technologies Completes Proof-of-Concept Studies at Preventing Miscarriages Using Stem Cell Immunotherapy Clinical Stage Erectile Dysfunction Company Expands Product Pipeline into Reproductive Immunology PHOENIX, June 21, 2016 /PRNewswire/ -- Creative Medical Te
Read more →CELZAgreement AGREEMENT This agreement is entered into by and between MIDDLE EAST GENERAL CONSULTING LTD (hereinafter referred to as Finder or MEGC ), and JOLLEY MARKETING, INC. (hereinafter referred to as JLLM or the Compan
This agreement is entered into by and between MIDDLE EAST GENERAL CONSULTING LTD (hereinafter referred to as Finder or MEGC ), and JOLLEY MARKETING, INC. (hereinafter referred to as "JLLM" or the Company ). The Agreement is effective as of July 15, 2015 (the "Effective Date"). T
Read more →Competitive Position
How CELZ ranks across every disease it competes inCompetitive Position is a premium feature
See how CELZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial